Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Consultant Clinical Oncologist
Dr Tait is Consultant Clinical Oncologist based at the Rutherford Cancer Centre in Thames Valley, she has been at The Royal Marsden since 1988 and has a specialist interest in upper gastrointestinal (GI), colorectal, hepatobiliary, anal and breast cancers.
Dr Tait was Vice-President and Dean for the Faculty of Clinical Oncology at Royal College of Radiologists from 2012-2014. She was involved in National committees looking at the delivery and redesign of radiotherapy services. She Chaired numerous National committees to continue and implement modern radiotherapy techniques and chemotherapy to improve the quality of care for oncology patients. She has worked with Macmillan Cancer Support in a number of different capacities and remains on their Expert Advisory Board.
Dr Tait is a Trustee for Bowel Cancer UK and a member of their Medical Advisory Committee. She is Senior Associate Editor (GI Team) for the premier international journal, The International Journal of Radiation Oncology, Biology and Physics (Red Journal) from 2018- present.
Areas of interest: Dr Diana Tait has a particular interest in GI chemoradiotherapy and the use of modern radiotherapy techniques, to optimise treatment for patients.
Research Interests: Dr Tait’s main research interests focus on using new radiotherapy technologies to improve treatment delivery, reduce side effects and improve patient outcomes. She has a special interest in the late consequences of treatment and survivorship issues.
If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or
© Copyright Rutherford Health Plc 2017 - 2022
All rights Reserved